Novel Tumor Subgroups of Urothelial Carcinoma of the Bladder Defined by Integrated Genomic Analysis

Purpose: There is a need for improved subclassification of urothelial carcinoma (UC) at diagnosis. A major aim of this study was to search for novel genomic subgroups. Experimental design: We assessed 160 tumors for genome-wide copy number alterations and mutation in genes implicated in UC. These comprised all tumor grades and stages and included 49 high-grade stage T1 (T1G3) tumors. Results: Our findings point to the existence of genomic subclasses of the “gold-standard” grade/stage groups. The T1G3 tumors separated into 3 major subgroups that differed with respect to the type and number of copy number events and to FGFR3 and TP53 mutation status. We also identified novel regions of copy number alteration, uncovered relationships between molecular events, and elucidated relationships between molecular events and clinico-pathologic features. FGFR3 mutant tumors were more chromosomally stable than their wild-type counterparts and a mutually exclusive relationship between FGFR3 mutation and overrepresentation of 8q was observed in non-muscle-invasive tumors. In muscle-invasive (MI) tumors, metastasis was positively associated with losses of regions on 10q (including PTEN), 16q and 22q, and gains on 10p, 11q, 12p, 19p, and 19q. Concomitant copy number alterations positively associated with TP53 mutation in MI tumors were losses on 16p, 2q, 4q, 11p, 10q, 13q, 14q, 16q, and 19p, and gains on 1p, 8q, 10q, and 12q. Significant complexity was revealed in events affecting chromosome 9. Conclusions: These findings may lead to improved biologic understanding and the development of prognostic biomarkers. Novel regions of copy number alteration may reveal potential therapeutic targets. Clin Cancer Res; 18(21); 5865–77. ©2012 AACR.

[1]  N. Malats,et al.  FGFR3 and Tp53 Mutations in T1G3 Transitional Bladder Carcinomas: Independent Distribution and Lack of Association with Prognosis , 2005, Clinical Cancer Research.

[2]  S. Davis,et al.  Exome sequencing identifies GRIN2A as frequently mutated in melanoma , 2011, Nature Genetics.

[3]  Zoltan Szallasi,et al.  Amplification of LAPTM4B and YWHAZ contributes to chemotherapy resistance and recurrence of breast cancer , 2010, Nature Medicine.

[4]  K. Rieger-Christ,et al.  A MicroRNA expression profile defining the invasive bladder tumor phenotype. , 2011, Urologic oncology.

[5]  M. Knowles.  Molecular subtypes of bladder cancer: Jekyll and Hyde or chalk and cheese? , 2006, Carcinogenesis.

[6]  Mattias Höglund,et al.  Combined gene expression and genomic profiling define two intrinsic molecular subtypes of urothelial carcinoma and gene signatures for molecular grading and outcome. , 2010, Cancer research.

[7]  E. Zwarthoff,et al.  Fibroblast growth factor receptor 3 mutations in bladder tumors correlate with low frequency of chromosome alterations. , 2008, Neoplasia.

[8]  M. Kuwano,et al.  The association of death-associated protein kinase hypermethylation with early recurrence in superficial bladder cancers. , 2002, Cancer research.

[9]  Paul Cairns,et al.  Genome-wide genetic characterization of bladder cancer: a comparison of high-density single-nucleotide polymorphism arrays and PCR-based microsatellite analysis. , 2003, Cancer research.

[10]  Peter A. Jones,et al.  Unique DNA methylation patterns distinguish noninvasive and invasive urothelial cancers and establish an epigenetic field defect in premalignant tissue. , 2010, Cancer research.

[11]  C. Abbou,et al.  Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors. , 2001, The American journal of pathology.

[12]  Antonio Alcaraz,et al.  MicroRNA in prostate, bladder, and kidney cancer: a systematic review. , 2011, European urology.

[13]  M. Gleave,et al.  Hsp27 promotes insulin-like growth factor-I survival signaling in prostate cancer via p90Rsk-dependent phosphorylation and inactivation of BAD. , 2010, Cancer research.

[14]  W. Gregory,et al.  Spectrum of Phosphatidylinositol 3-Kinase Pathway Gene Alterations in Bladder Cancer , 2009, Clinical Cancer Research.

[15]  L. Sobin,et al.  Histological Typing of Urinary Bladder Tumours , 1999, International Histological Classification of Tumours.

[16]  Carsten Wiuf,et al.  Role of Activating Fibroblast Growth Factor Receptor 3 Mutations in the Development of Bladder Tumors , 2005, Clinical Cancer Research.

[17]  J. Jen,et al.  Genomic organization and mutation analysis of Hel-N1 in lung cancers with chromosome 9p21 deletions. , 1997, Cancer research.

[18]  N. Malats,et al.  PIK3CA mutations are an early genetic alteration associated with FGFR3 mutations in superficial papillary bladder tumors. , 2006, Cancer research.

[19]  Anne-Mette K. Hein,et al.  Gene Expression Signatures Predict Outcome in Non–Muscle-Invasive Bladder Carcinoma: A Multicenter Validation Study , 2007, Clinical Cancer Research.

[20]  Carsten Wiuf,et al.  High-density single nucleotide polymorphism array defines novel stage and location-dependent allelic imbalances in human bladder tumors. , 2005, Cancer research.

[21]  H Snowden,et al.  AKT1 mutations in bladder cancer: identification of a novel oncogenic mutation that can co-operate with E17K , 2010, Oncogene.

[22]  Carsten Wiuf,et al.  Comprehensive Genome Methylation Analysis in Bladder Cancer: Identification and Validation of Novel Methylated Genes and Application of These as Urinary Tumor Markers , 2011, Clinical Cancer Research.

[23]  C. Cordon-Cardo,et al.  Inactivation of p53 and Pten promotes invasive bladder cancer. , 2009, Genes & development.

[24]  M. Höglund,et al.  A Systematic Study of Gene Mutations in Urothelial Carcinoma; Inactivating Mutations in TSC2 and PIK3R1 , 2011, PloS one.

[25]  Mattias Höglund,et al.  Tiling resolution array CGH and high density expression profiling of urothelial carcinomas delineate genomic amplicons and candidate target genes specific for advanced tumors , 2008, BMC Medical Genomics.

[26]  J. Komorowski,et al.  Focal amplifications are associated with high grade and recurrences in stage Ta bladder carcinoma , 2009, International journal of cancer.

[27]  K. Maclennan,et al.  A computational index derived from whole-genome copy number analysis is a novel tool for prognosis in early stage lung squamous cell carcinoma. , 2012, Genomics.

[28]  Mårten Fernö,et al.  A Molecular Taxonomy for Urothelial Carcinoma , 2012, Clinical Cancer Research.

[29]  Sami Kilpinen,et al.  High‐resolution copy number and gene expression microarray analyses of head and neck squamous cell carcinoma cell lines of tongue and larynx , 2008, Genes, chromosomes & cancer.

[30]  T. Ørntoft,et al.  Consistent genomic alterations in carcinoma in situ of the urinary bladder confirm the presence of two major pathways in bladder cancer development , 2009, International journal of cancer.

[31]  N. Carter,et al.  DNA microarrays for comparative genomic hybridization based on DOP‐PCR amplification of BAC and PAC clones , 2003, Genes, chromosomes & cancer.

[32]  Huanming Yang,et al.  Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladder , 2011, Nature Genetics.

[33]  D. F. Thomas,et al.  Normal human urothelial cells in vitro: proliferation and induction of stratification. , 1994, Laboratory investigation; a journal of technical methods and pathology.

[34]  Wen-Lin Kuo,et al.  Array-based comparative genomic hybridization for genome-wide screening of DNA copy number in bladder tumors. , 2003, Cancer research.

[35]  Xue-Ru Wu.  Urothelial tumorigenesis: a tale of divergent pathways , 2005, Nature Reviews Cancer.

[36]  H. Ozen.  Bladder cancer. , 1998, Current opinion in oncology.

[37]  J Alfred Witjes,et al.  Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. , 2006, European urology.

[38]  Joel H. Saltz,et al.  The Proneural Molecular Signature Is Enriched in Oligodendrogliomas and Predicts Improved Survival among Diffuse Gliomas , 2010, PloS one.

[39]  Karen Albert.  Journal of the National Comprehensive Cancer Network (JNCCN) , 2005 .

[40]  J. Califano,et al.  Methylation of the DFNA5 increases risk of lymph node metastasis in human breast cancer. , 2008, Biochemical and biophysical research communications.

[41]  N. Carter,et al.  High-resolution analysis of genomic copy number alterations in bladder cancer by microarray-based comparative genomic hybridization , 2004, Oncogene.

[42]  H. Okano,et al.  Involvement of Hu and Heterogeneous Nuclear Ribonucleoprotein K in Neuronal Differentiation through p21 mRNA Post-transcriptional Regulation* , 2005, Journal of Biological Chemistry.

[43]  F. Algaba,et al.  Comparative genomic hybridization analysis reveals new different subgroups in early-stage bladder tumors. , 2010, Urology.

[44]  H. von der Maase,et al.  Allelic imbalances in human bladder cancer: genome-wide detection with high-density single-nucleotide polymorphism arrays. , 2002, Journal of the National Cancer Institute.

[45]  A. Clarke,et al.  Lkb1 and Pten Synergise to Suppress mTOR-Mediated Tumorigenesis and Epithelial-Mesenchymal Transition in the Mouse Bladder , 2011, PloS one.

[46]  F. Hosoda,et al.  Copy number alterations in urothelial carcinomas: their clinicopathological significance and correlation with DNA methylation alterations , 2010, Carcinogenesis.

[47]  R. Pfundt,et al.  Genomic and expression profiling of human spermatocytic seminomas: primary spermatocyte as tumorigenic precursor and DMRT1 as candidate chromosome 9 gene. , 2006, Cancer research.

[48]  K. Wong,et al.  Genome-wide allelic imbalance analysis of pediatric gliomas by single nucleotide polymorphic allele array. , 2006, Cancer research.

[49]  Johan Staaf,et al.  Integrated Genomic and Gene Expression Profiling Identifies Two Major Genomic Circuits in Urothelial Carcinoma , 2012, PloS one.

[50]  Å. Borg,et al.  MiRNA expression in urothelial carcinomas: Important roles of miR‐10a, miR‐222, miR‐125b, miR‐7 and miR‐452 for tumor stage and metastasis, and frequent homozygous losses of miR‐31 , 2009, International journal of cancer.

[51]  Elena Marchiori,et al.  Breakpoint identification and smoothing of array comparative genomic hybridization data , 2004, Bioinform..